Vutrisiran: Difference between revisions
Content deleted Content added
ce |
added missing data to cite |
||
| Line 43: | Line 43: | ||
| legal_UK_comment = |
| legal_UK_comment = |
||
| legal_US = Rx-only |
| legal_US = Rx-only |
||
| legal_US_comment = <ref name="Alnylam PR 20220613">{{cite web | title=Alnylam Announces FDA Approval of Amvuttra (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults | publisher=Alnylam | via=Business Wire | date=13 June 2022 | url=https://www.businesswire.com/news/home/20220603005487/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA%E2%84%A2-vutrisiran-an-RNAi-Therapeutic-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults | access-date=14 June 2022 | archive-date=14 June 2022 | archive-url=https://web.archive.org/web/20220614055318/https://www.businesswire.com/news/home/20220603005487/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA%E2%84%A2-vutrisiran-an-RNAi-Therapeutic-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults | url-status=live }}</ref><ref>{{Cite web |url=https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf |title= |
| legal_US_comment = <ref name="Alnylam PR 20220613">{{cite web | title=Alnylam Announces FDA Approval of Amvuttra (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults | publisher=Alnylam | via=Business Wire | date=13 June 2022 | url=https://www.businesswire.com/news/home/20220603005487/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA%E2%84%A2-vutrisiran-an-RNAi-Therapeutic-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults | access-date=14 June 2022 | archive-date=14 June 2022 | archive-url=https://web.archive.org/web/20220614055318/https://www.businesswire.com/news/home/20220603005487/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA%E2%84%A2-vutrisiran-an-RNAi-Therapeutic-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults | url-status=live }}</ref><ref>{{Cite web |url=https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf |title=AMVUTTRA (vutrisiran) prescribing information |access-date=14 June 2022 |archive-date=14 June 2022 |archive-url=https://web.archive.org/web/20220614055259/https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf |url-status=live | publisher = Alnylam Pharmaceuticals, Inc. | location = Cambridge, MA }}</ref> |
||
| legal_EU = |
| legal_EU = |
||
| legal_EU_comment = |
| legal_EU_comment = |
||
Revision as of 10:57, 14 June 2022
| Clinical data | |
|---|---|
| Trade names | Amvuttra |
| Other names | ALN-65492 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| UNII |
|
| KEGG | |
Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.[1]
Vutrisiran was approved for medical use in the United States in June 2022.[1]
Vutrisiran is the international nonproprietary name (INN).[3]
History
The U.S. Food and Drug Administration (FDA) granted the application for vutrisiran orphan drug designation.[4]
References
- ^ a b c "Alnylam Announces FDA Approval of Amvuttra (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults". Alnylam. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 14 June 2022 – via Business Wire.
- ^ "AMVUTTRA (vutrisiran) prescribing information" (PDF). Cambridge, MA: Alnylam Pharmaceuticals, Inc. Archived (PDF) from the original on 14 June 2022. Retrieved 14 June 2022.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
- ^ "Vutrisiran Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 25 May 2018. Retrieved 14 June 2022.
External links
- "Vutrisiran". Drug Information Portal. U.S. National Library of Medicine.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |